drugset / Trial / NCT03058224
Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia
Completed
230 enrolled
IgNova GmbH
CenTrial GmbH · collabKlinar CRO · collabPharmasolutions4U · collabScope International AG · collabidv Data Analysis and Study Planning · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled exploratory trial to investigate efficacy and safety of food supplement IGN-ES001 in patients with chronic widespread pain (CWP) with or without fibromyalgia (FM).
Timeline
- Start
- 2017-02-16
- Primary completion
- 2017-11-30
- Completion
- 2017-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IGN-ES001 | Unknown | — | — |
| Background | Acetaminophen | Small molecule | 500 mg | — |